Finasteride – Kodiac biolabs

Plain-language summaryIntrigue 65 / 100

Finasteride (Proscar at 5 mg, Propecia at 1 mg) is a 1990s drug that blocks the type II 5-alpha-reductase enzyme, which converts testosterone into the more potent dihydrotestosterone (DHT) in the prostate, scalp, and skin. It cuts plasma DHT by about 65 to 70 percent at the 5 mg dose. Approved for benign prostate enlargement and male-pattern hair loss, with both indications driven by reducing local DHT. The hair-loss application is the famous one. Side effects include sexual dysfunction in a minority of users, with persistent symptoms after discontinuation (post-finasteride syndrome) reported in case series, though the frequency and biological basis remain debated. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

46/100

The reference Type II 5AR inhibitor, mature and well-characterized, with real probe value but limited novelty

Look, finasteride is a 30-year-old approved drug with a completely characterized mechanism. That’s not a knock on it, thats just what it is. FDA cleared in 1992 for BPH and 1997 for androgenetic alopecia, it became the reference standard Type II-selective 5-alpha-reductase inhibitor in androgen biology research, and that’s the best argument for including it in a research library at all.

The mechanism is specific: finasteride inhibits the Type II isozyme (Ki approximately 10 nM) without meaningfully touching Type I, which lives in liver, skin, and the brain. Dutasteride hits both, dropping plasma DHT by around 95 percent. Finasteride gets you 65 to 70 percent at the 5 mg dose. That gap is actually what makes finasteride interesting on the bench, not therapeutically, but as a probe. If you want to ask what Type I versus Type II 5AR contributes to a given phenotype, finasteride is your tool. That question comes up in androgen pathway work, in skin biology, and increasingly in neurosteroid research.

The neurosteroid angle is genuinely the most interesting current research use. Finasteride inhibits the conversion of progesterone to 5-alpha-dihydroprogesterone, which is upstream of allopregnanolone synthesis. Allopregnanolone is a positive GABA-A allosteric modulator, and its reduction is one proposed mechanism behind what is now called post-finasteride syndrome (PFS). We dont want to over-claim here, the literature is contested and the mechanistic case is still being built, but the neurosteroid deprivation hypothesis has generated serious laboratory work, including papers from the Melcangi group at the University of Milan examining central nervous system steroid profiles after finasteride exposure in rodent models. Thats real bench science with real questions still open.

What works against a high score is straightforward: the compound isn’t novel, the core mechanism is completely solved, and for pure androgen pathway intervention dutasteride offers a more complete picture. Finasteride is useful because it’s the Type II selective option, not because it’s doing anything pharmacologically surprising. Its evidence quality and translational signal are excellent precisely because it’s a mature approved drug with decades of large-scale human data. Those scores pull the overall up, but they shouldn’t, because well-characterized evidence on a boring old mechanism isn’t research excitement.

We think of finasteride as a mature tool with a specific probe niche. It earns a spot as the reference Type II 5AR inhibitor and as a gateway into the PFS neurosteroid literature, but it’s not a compound that any serious investigator has on their want-to-study-more list in 2025 unless the question is specifically about Type I versus Type II isozyme contributions or GABA-A neurosteroid circuitry.

Novelty: 20
Mechanism promise: 25
In-category differentiation: 35
Evidence quality: 85
Translational signal: 75
Research bench value: 60

Rationale FDA-approved since 1992 with fully characterized mechanism and massive clinical evidence base; earns a library spot as the selective Type II 5AR probe in androgen and neurosteroid research, but novelty and differentiation scores are low because the mechanism is completely understood and dutasteride covers the therapeutic space more completely for most applications.

5-alpha-reductase type II inhibitor

A 4-azasteroid 5-alpha-reductase type II inhibitor; approved for benign prostatic hyperplasia and androgenetic alopecia.

Abstract

Finasteride (N-(2-methyl-2-propanyl)-3-oxo-(5-alpha,17-beta)-4-azaandrost-1-ene-17-carboxamide; CAS 98319-26-7; molecular formula C23H36N2O2; molecular weight 372.55) is a 4-azasteroid 5-alpha-reductase inhibitor developed at Merck and approved by the FDA in 1992 (Proscar 5 mg for BPH) and 1997 (Propecia 1 mg for androgenetic alopecia). Mechanism: selective inhibition of 5-alpha-reductase type II isozyme (Ki approximately 10 nM), which converts testosterone to dihydrotestosterone (DHT) in prostate, hair follicle, and skin. Plasma DHT is reduced by approximately 65 to 70 percent at the 5 mg dose. Type I 5AR (in liver, skin, and brain) is largely unaffected. Plasma half-life is approximately 6 to 8 hours; metabolism is via CYP3A4. The compound has well-documented sexual side effects (reduced libido, erectile dysfunction in approximately 1 to 5 percent of users) and the controversial post-finasteride syndrome (persistent symptoms after discontinuation, debated as a clinical entity). Used as the reference 5AR-II selective inhibitor in mechanism studies and as a positive control in androgen pathway research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-279Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.